Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 1;187(11):5720-32.
doi: 10.4049/jimmunol.1102195. Epub 2011 Nov 2.

Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses

Affiliations

Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses

Sreemanti Basu et al. J Immunol. .

Abstract

The endocannabinoid system has emerged as an important regulator of immune responses, with the cannabinoid receptor 2 (CB2) and its principle ligand 2-archidonoylglycerol playing a major role. How CB2 regulates B cell functions is not clear, even though they express the highest levels of CB2 among immune cell subsets. In this study, we show that CB2-deficient mice have a significant reduction in the absolute number of marginal zone (MZ) B cells and their immediate precursor, transitional-2 MZ precursor. The loss of MZ lineage cells in CB2(-/-) mice was shown to be B cell intrinsic using bone marrow chimeras and was not due to a developmental or functional defect as determined by B cell phenotype, proliferation, and Ig production. Furthermore, CB2(-/-) B cells were similar to wild type in their apoptosis, cell turnover, and BCR and Notch-2 signaling. We then demonstrated that CB2(-/-) MZ lineage B cells were less efficient at homing to the MZ and that their subsequent retention was also regulated by CB2. CB2(-/-) mice immunized with T-independent Ags produced significantly less Ag-specific IgM. This study demonstrates that CB2 positively regulates T-independent immune responses by controlling the localization and positioning of MZ lineage cells to the MZ.

PubMed Disclaimer

Figures

Figure 1
Figure 1. T2-MZP and MZ B cells are significantly reduced in the absence of CB2
(A, B) Splenocytes from WT and CB2−/− mice were stained for B220, IgM, CD21, CD23 and CD93 to identify T1 (B220+IgMhiCD21lo/−CD23CD93+), T2 (B220+IgMhiCD21lo/−CD23+CD93+), Fo (B220+IgMintCD21intCD23+CD93), T2-MZP (B220+IgMhiCD21hiCD23+), and MZ B cells (B220+IgMhiCD21hiCD23) by flow cytometry. (A) WT (white bar) and CB2−/− (black bar) B cells were gated for B220 and the percentage (upper panel) and absolute number (bottom panel) of the indicated B cell subsets is shown. (B) Representative contour plots show relative frequencies of B220-gated IgMhiCD21hi (T2-MZP + MZ) B cells (left panel) and T2-MZP and MZ B cells separately (middle panels) from WT (top panels) or CB2−/− (bottom panels) mice. Numbers on the plots represent the percentage of cells in the corresponding gate. The cumulative percentage and absolute number of T2-MZP and MZ B cells is shown (right panel). (A,B) Data are the mean ± SEM from five independent experiments (n=10 mice/group). (C) Seven µm frozen spleen sections from WT and CB2−/− mice were stained with anti-IgM (red) and anti-IgD (green) to indicate MZ B cells (IgMhi, thick arrows) and B cell follicles (IgDhi, arrowheads), respectively. Magnification is 100x. Data is representative of two independent experiments (n=2). *p <0.05; ***p <0.005.
Figure 2
Figure 2. B cell intrinsic CB2 requirement for the homeostasis/maintenance of T2-MZP and MZ B cells
(A) Splenic CD4 T (TCRβ+CD4+), Fo, T2-MZP and MZ B cells (phenotypted as for Fig. 1) from WT mice were purified by FACS. CNR2 gene expression was determined by quantitative real-time PCR. Relative CNR2 expression was calculated from a GAPDH standard curve. Data are cumulative from three independent experiments each comprised of pooled cells from 2–3 mice. (B) CD45.1 WT BM (white bar) was mixed with CD45.2 WT (gray bar) (upper left panel) or CD45.2 CB2−/− (black bar) (lower panels) BM in a 1:1 (leftt panels) or 1:4 (lower right panel) ratio and transplanted into lethally irradiated µMT mice. After 10–12 weeks of reconstitution the percentages of CD45.1 and CD45.2 cells were determined in the Fo, T2-MZP and MZ B cell populations. Data shown are the mean ± SEM of one representative experiment of three with four-five mice per group. **p <0.01.
Figure 3
Figure 3. CB2-deficiency does not lead to altered apoptosis, reduced turnover or changes in BCR or Notch-2 signaling in T2-MZP and MZ B cells
(A) Splenocytes from WT (white bar) and CB2−/− (black bar) mice were stained with anti-B220, IgM, CD21, CD23 and CD93 antibodies to identify T2-MZP and MZ B cells (as for Fig. 1). Intracellular staining was performed to determine the percentage of cells containing active-caspase-3. Data shown are the mean ± SEM of two experiments (n=6) (B,C) BrdU (0.8 mg/ml) was administered in the drinking water for 16 h (B) or continuously for nine days (C) to WT and CB2−/− mice and the percentage of T2-MZP and MZ B cells that incorporated BrdU was analyzed on the indicated days. Data represent a single experiment with three-four mice per group. All data are shown as the mean ± SEM. * p < 0.05. (D) Splenocytes from WT (gray line) and CB2−/− (black line) mice were stained to identify T2 B cells and loaded with Indo-1 AM for 30 min. After base line establishment, B cells were stimulated with 10 µg of F(ab’)2 fragment goat anti-mouse IgM in the absence or presence of 100 nM or 1 µM 2-AG. Calcium mobilization was evaluated by measuring the fluorescence ratio of Indo-1 AM (405 nm/530 nm). Two independent experiments of four are shown (n = 4). (E) Splenic Fo, T2-MZP and MZ B cells from WT (white bar) and CB2−/− (black bar) mice were purified by FACS and the expression of RBP-J, Hes-1 and Deltex-1 genes was quantified by real-time PCR. Relative gene expression was calculated from a GAPDH standard curve. Data are shown as the mean ± SEM of three independent experiments with each containing cells pooled from 2–3 mice.
Figure 4
Figure 4. The endogenous CB2 ligand 2-AG induces chemotaxis of WT B cells in a CB2-dependent manner
RBC and macrophage-depleted splenocytes (1 × 106) from WT or CB2−/− mice were placed in the upper chamber of a five µm Transwell and allowed to migrate towards medium + vehicle or 2-AG (1–10 µM) in the lower chamber for 3h. Migrated cells were collected from the lower chamber and Fo, T2-MZP and MZ B cells were detected by flow cytometry as for Fig. 1. Migration was measured as the percentage of input cells. Data are shown as the mean ± SEM of five independent experiments. **p <0.01.
Figure 5
Figure 5. CB2 is required for efficient homing and retention of T2-MZP and MZ B cells
(A, B) WT and CB2−/− B cells were labeled with Cell Tracker Violet or CFSE, respectively, mixed in 1:1 ratio (input cells) and adoptively transferred into WT recipients. A fraction of the input cells was labeled for Fo, T2-MZP and MZ B cells (as in Fig. 1) and analyzed by flow cytometry to determine the ratio of CB2−/− to WT cells in each B cell subset (Input ratio) (A). After 4 h of adoptive transfer, 1 µg of CD21-PE was administered (i.v.) to recipient mice for 20 min to specifically label MZ-residing B cells. Subsequently, spleens were processed and stained to distinguish Fo, T2-MZP and MZ B cells. In each CD21-PE+ B cell subset, the proportion of WT (Cell Tracker Violet+) and CB2−/− (CFSE+) was determined by flow cytometry. The same assay was also carried out with reversely labeled WT and CB2−/− B cells, and the data are combined. (A) Representative dot plots show proportions of WT and CB2−/− cells in the input (upper panel), and recipient (bottom panel) T2-MZP or MZ B populations. (B) Homing ratio of CB2−/−/WT cells in the CD21-PE+ T2-MZP (gray bar) and MZ (black bar) B cell fractions, as calculated by dividing the ratio of CB2−/−/WT cells post-homing by the input ratio. Data are cumulative from three independent experiments with 3 mice per group. The homing ratio is indicated. (C–E) WT mice were treated (i.v.) with 10 µg of SR144528 (black bar) or vehicle (1% ethanol) (white bar) for 4 h, and B cells from the spleen and blood were analyzed by flow cytometry. (C) Representative contour plots show relative frequencies of B220-gated IgMhiCD21hi (T2-MZP + MZ) B cells (left) and T2-MZP and MZ B cells separately (right panels) within B220-gated cells after vehicle (top panels) or SR144528 (bottom panels) treatment. Numbers on the plots represent the percentage of cells in the corresponding gates. (D) Percentage of B220+ (upper panel) and the subsequent absolute number (bottom panel) of Fo, T2-MZP and MZ B cell subsets is shown. (E) The absolute number of IgMhiCD21hi (T2-MZP + MZ) B cells/ml in the blood. Data shown are the mean ± SEM from two independent experiments each with 3–4 mice per group. *p <0.05; **p <0.01.
Figure 6
Figure 6. CB2-deficiency leads to decreased T2-MZP and MZ B cells in the MZ compartment increasing their numbers in the blood
(A,B) Anti-CD21-PE (0.25–1 µg) was i.v. administered to WT and CB2−/− mice and after 20 min splenocytes were isolated and stained to identify T2-MZP and MZ B cells (as for Fig. 1) that had localized to the MZ (CD21PE+). (A) Representative histograms show relative frequencies of CD21-PE+ (right gate) T2-MZP (left panels) and MZ (right panels) B cells. Background fluorescence was determined by mixing CD45.1+ splenic tissue from unmanipulated mice to splenic tissue of CD21-PE-labeled (CD45.2+) mice prior to processing and staining. Background fluorescent gates (left gate) were set on CD45.1+CD21-PE T2-MZP or MZ B cells. Numbers on the plots represent the percentage of cells in the corresponding gate. (B) Percentages of CD21-PE+ (left panel) and CD21-PE (right panel) WT (white bar) and CB2−/− (black bar) T2-MZP and MZ B cells. Data shown are the mean ± SEM of four independent experiments (n=10). (C,D) Peripheral blood from WT and CB2−/− mice was stained and analyzed for IgMhiCD21hi (T2-MZP + MZ) B cells. (C) Representative contour plots showing the relative frequencies of IgMhiCD21hi cells in the peripheral blood. Numbers on the plots represent the percentage of cells in the corresponding gate. (D) The absolute number of WT (white bar) and CB2−/− (black bar) IgMhiCD21hi cells/ml in the peripheral blood. Data shown are the mean ± SEM of two independent experiments each with three mice per group. **p <0.01; ***p <0.005
Figure 7
Figure 7. CB2 deficiency leads to diminished T-independent humoral immune responses
(A) Sera was collected from 8–12 week WT (open symbol) and CB2−/− (closed symbol) mice and total serum IgM, IgG1, IgG2b, IgG2c, IgG3, IgA levels were measured by ELISA. Each symbol represents a single mouse. (B, C) WT (open symbol) and CB2−/− (closed symbol) mice were immunized (i.p.) with 30 µg of NP-Ficoll (B). Blood was collected on days 0, 7 and 14 and NP-specific IgM and IgG3 titers were determined from 1:2 serially diluted sera by ELISA. Data shown are the mean ± SEM of one representative of three independent experiments each with 3–5 mice per group. (C) Spleens were collected 6–7 days post-immunization and NP-specific IgM secreting B cells in the spleen were enumerated by ELISPOT. Data shown are the mean ± SEM of three independent experiments (n = 9). (D) WT (white bar) and CB2−/− (black bar) mice were immunized (i.p.) with 23 µg of Pneumovax 23. Blood was collected on days 0, 7 and 14 and Pneumovax-specific IgM levels were measured from serially diluted sera (1:25 to 1:1875; O.D. from 1:625 dilution is shown) by ELISA. Data shown are the mean ± SEM of two independent experiments (n = 6). *p <0.05; **p <0.005

References

    1. Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulaton in health and disease. Immunol. Res. 2011 - PMC - PubMed
    1. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995;50:83–90. - PubMed
    1. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. - PubMed
    1. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65. - PubMed
    1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564. - PubMed

Publication types

Substances